Additional file 4: Figure S2. of Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells

Proliferation rate of melanoma cells. Cell proliferation of the indicated melanoma cell lines assessed by monitoring impedance by RTCA xCELLigence system. The reported doubling times were calculated from the cell growth curves, during exponential growth. Data represent mean ± SD from a quadruplicate experiment representative of 3 replicates. (PDF 120 kb

Additional file 1: Figure S1. of Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells

Uncropped images of immunoblots. Full blots from Fig. 1b, Inset of the Fig. 2a, c, Fig. 4b, and Fig. 7a. (PDF 164 kb

Additional file 1: of Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Table S1A. Cox regression models on overall survival in patients with brain metastases (DOCX 15 kb

Additional file 2: of Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Figure S1. Kaplan-Maier OS and PFS curves of melanoma patient treated with nivolumab. (A) Patients stratified according baseline median ANC as cutoff . Green line: ANC≥5.4; Blue line: ANC<5.4. (B) Patients stratified for PFS according baseline median ANC as cut-off . Green line: ANC≥5.4; Blue line: ANC<5.4. Figure S2. Kaplan-Maier OS and PFS curves of melanoma patient treated with nivolumab using optimal cutoff for derived neutrophils-to lymphocyte ratio (dNLR). (A)) Patients stratified according baseline dNLR. Green line: dNLR≥3.8; Blue line: dNLR<3.8. (DOCX 168 kb

MOESM2 of Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Additional file 2. MedDRA-preferred terms relevant to serous retinopathy